Charles Schwab Investment Management Inc Satsuma Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$4.54 - $7.17 $99,916 - $157,797	-22,008 Reduced 64.11%	12,319 $58,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $103,478 - $156,295	-21,558 Reduced 38.58%	34,327 $243,000
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $8,134 - $12,780	1,780 Added 3.29%	55,885 $331,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $3,349 - $4,789	-941 Reduced 1.71%	54,105 $250,000
Q3 2020 Nov 13, 2020	BUY	$3.85 - $28.47 $36,963 - $273,340	9,601 Added 21.13%	55,046 $215,000
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $249,275 - $540,123	15,570 Added 52.12%	45,445 $1.31 Million
Q1 2020 May 15, 2020	SELL	$14.53 - $30.69 $52,889 - $111,711	-3,640 Reduced 10.86%	29,875 $643,000
Q4 2019 Feb 07, 2020	BUY	$9.32 - $19.68 $312,359 - $659,575	33,515 New	33,515 $660,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.